bupropion

(redirected from Budeprion)
Also found in: Dictionary.
Related to Budeprion: Budeprion SR, Budeprion XL

bupropion

 [bu-pro´pe-on]
a compound structurally similar to amphetamine, used in the form of the hydrochloride salt as an antidepressant and as an aid in smoking cessation to reduce the symptoms of nicotine withdrawal; administered orally.

bupropion

/bu·pro·pi·on/ (bu-pro´pe-on) a monocyclic compound structurally similar to amphetamine, used as the hydrochloride salt as an antidepressant and as an aid in smoking cessation.

bupropion

(byo͞o-prō′pē-ŏn′)
n.
A drug, C13H18ClNO, used in its hydrochloride form for the treatment of depression and as an aid in smoking cessation. It is a weak inhibitor of norepinephrine and dopamine reuptake in the central nervous system.

buPROPion

[boo͡prō′pē·on]
a heterocyclic mood-elevating drug used to treat some types of depression (trademark: Wellbutrin) and also to promote smoking cessation (trademark: Zyban).

bupropion

Zyban® Psychiatry An antidepressant Side effects Dry mouth, insomnia Contraindications Seizures, bulimia

bupropion

A drug used in the treatment of tobacco, drug and alcohol dependency. Bupropion reacts adversely with a wide range of other drugs and may induce seizures in sensitive persons. When used, a strict regime is necessary. A brand name is Zyban.

Bupropion

An antidepressant medication given to smokers for nicotine withdrawal symptoms. It is sold under the trade name Zyban.

bupropion (byōō´prō´pēon),

n brand names: Wellbutrin, Zyban;
drug class: antidepressant;
action: weak uptake inhibitor of dopamine, serotonin, norepinephrine; mechanism unknown;
uses: treatment of depression and anxiety disorders; tobacco cessation.
References in periodicals archive ?
The chart below (21) shows the results of bioequivalence tests of the two drugs by measuring concentration of medicine over time for the 150 mg doses of Budeprion and Wellbutrin XL.
It found that the maximum concentration of Budeprion XL 300 in the blood plasma reached only 75 percent of the amount Wellbutrin XL 300 released, and, in some volunteers, the level never reach 40%.
Withdrawal of generic budeprion for nonbioequivalence.
57) Questions and Answers Regarding Market Withdrawal of Budeprion XL 300 mg Manufactured by Impax and Marketed by Teva; U.
This was recently shown in the comparison between branded bupropion XL 300 mg and generic Budeprion XL 300 mg.
Budeprion XL 300mg not therapeutically equivalent to Wellbutrin 300 mg.
The planned withdrawal of Budeprion XL 300 mg is the result of studies conducted by the company and FDA aimed at addressing reports of reduced efficacy from patients who were switched to generic forms of Wellbutrin XL 300 mg made more than 5 years ago.
According to the December 2, 2009 article, the proposed study will enroll 138 patients who complained after switching from Wellbutrin XL([R]) 300 mg to Budeprion XL.
A statement in the article attributed to Teva's head of regulatory affairs suggests that the study will rely on blood-level data to verify bioequivalence of Wellbutrin XL([R]) and Budeprion XL.
Food and Drug Administration (FDA) has issued its report concerning the Therapeutic Equivalence of Generic Bupropion XL 300 mg and Wellbutrin XL 300 mg and found that our generic buproprion extended-release tablets, marketed as Budeprion XL 300 milligram by our partner Teva Pharmaceutical USA, is a safe and effective choice for consumers in treating depression.
s Risperdal; Budeprion XL 150 mg, AB rated to GlaxoSmithKline's Wellbutrin XL; alendronate sodium tablets, AB rated to Merck's Fosamax; zaleplon capsules, AB rated to King Pharmaceuticals Inc.
Products launched in 2006 include Simvastatin tablets, AB-rated and bioequivalent to Merck's Zocor; Pravastatin Sodium tablets, AB-rated and bioequivalent to Bristol-Myers Squibb's Pravachol; Sertraline Hydrochloride tablets, AB-rated and bioequivalent to Pfizer's Zoloft tablets; Ondanstron injection, AB-rated and bioequivalent to GSK's Zofran; Budeprion XL (Bupropion HC1 ER tablets), AB-rated and bioequivalent to Boehringer Ingelheim's Mobic.